Latest News Archive

Please select Category, Year, and then Month to display items

UFS students honoured at 2024 Women in Science Awards

23 August 2024 | Story André Damons | Photo Supplied

Thandokuhle Gama, Dr Glen Tylor and Anele Mthembu — Winners: Thandokuhle Gama (left) and Anele Mthembu (right), who were honoured with the DSI-Esther Mahlangu Master's Fellowship at the 2024 SAWiSA, with Dr Glen Taylor, Senior Director: Directorate Research Development (DRD), UFS.

Two postgraduate students from the University of the Free State (UFS) were honoured at this year’s Women in Science Awards (SAWiSA) hosted by the Department of Science and Innovation (DSI).

Thandokuhle Gama, a Master of Medical Science student with specialisation in Pharmacology, and Anele Mthembu, who is working on her master’s degree in Disaster Management in the Disaster Management Training and Education Centre for Africa (DIMTEC), are both recipients of the DSI-Esther Mahlangu Master's Fellowships.

This fellowship is awarded to women scientists and researchers who are pursuing their master’s or doctoral studies and already hold scholarships from the National Research Foundation or other DSI agencies. The fellowships for Gama and Mthembu are worth R75 000 each and can be used towards their tuition fees or to enhance academic programmes by covering the costs of attending conferences or specialised research materials and equipment required to complete their degrees.

Honouring Dr Esther Mahlangu

The prestigious 2024 SAWiSA, which honour the exceptional contributions of women to science, technology, engineering, mathematics and innovation (STEMI) in South Africa, took place on 15 August 2024 in Mbombela. The theme was “Transition towards an Innovation Economy: The Role of Women Leaders in STEM”.

This year, the awards honoured world-renowned artist, Dr Esther Mahlangu, by renaming this year's master's and doctoral fellowships the DSI-Esther Mahlangu Fellowships.

“I feel honoured and grateful for the recognition, although it's been difficult to process what it actually means. It has been an overwhelming experience. It came as a surprise, because when I applied, I was not sure what to expect because these are national awards with many other applicants,” says Gama.

She was nominated by Innocensia Mangoato, lecturer in the UFS Department of Pharmacology and a previous winner at the awards. Gama is doing research on medicinal plants that are used in traditional medicine to treat diabetes.

“Winning this award means that my work thus far is being recognised. It is all through God’s grace. I'm also grateful to everyone who has contributed towards my journey: my family, teachers, mentors and sponsors, and everyone else. It will allow me to continue to advance research in the field of diabetes treatment using traditional medicines or medicinal plants.”

Bettering lives

Mthembu, who was nominated by her mentor, Dr Tlou Daisy Raphela-Masuku, a lecturer at DIMTEC, says it is a fantastic feeling winning this award. “Before the awards, Dr Raphela-Masuku and I dreamt I could win the SAWiSA. But before then, I was surprised and grateful for being acknowledged by DSI as a finalist; I focused on being a DSI finalist, and that winning would be a bonus,” she says.

She continues: “It means a lot to me to win the DSI Master’s Fellowship, as it is a testimony of God’s grace in my life. It is the destiny for helpers God has placed in my life, including my mentor, supervisor, and the DIMTEC postgraduate school. We all won!”

Mthembu is working her master’s thesis on the integration of risk-informed development (RID) and nature-based solutions (NbS) into sustainable human settlements in eThekwini Municipality, KwaZulu-Natal.

“The overarching aim is to evaluate the integration of both these concepts into human settlements’ strategic planning to offer eThekwini Municipality innovative and ecosystem-based approaches to achieving sustainable and resilient human settlements and achieving Sustainable Development Goal (SDG) 11 on building resilient cities.

“I hope to publish my findings and contextualise the enabling environments for RID (EE4RID) Framework in eThekwini Municipality so they can make risk-informed decisions on development and human settlements to achieve SDG 11,” explains Mthembu.

Gama says the aim with her research is to determine if these medicinal plants can treat diabetes by stimulating stem cells to differentiate and become insulin-producing cells. She hopes that through this research diabetes treatment can advance from a level where it is being continuously managed, to a level where we can cure the disease.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease

2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013

The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.

In future further evaluation will be performed in other forms of hypocholesterolemia.

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.

Back

Economic and Management Sciences

Education

Health Sciences

The Humanities

Law

Natural and Agricultural Sciences

Theology and Religion

Open Distance Learning

Business School

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept